Corsera Health, a Boston-based biotech developing preventive heart disease medicines, raised an $80m Series A, it announced on 7 January 2026. Forbion and Population Health Partners co-led the round, which Forbion described as oversubscribed. Co-founder and co-CEO John Maraganore also invested, according to BioSpace and Forbion.
No valuation was disclosed. Marco Boorsma, a general partner at Forbion, will join Corsera's board, the investor said.
The announcement coincided with the first clinical milestone: dosing has started in a Phase 1 trial of the lead drug, a few months after the company emerged in September 2025.
“Corsera has the potential to change the trajectory of cardiovascular disease”John Maraganore, Co-Founder and Co-CEO, Corsera Health
What Corsera does
BioSpace reported that the company aims to extend healthspan by lowering the risk of atherosclerotic cardiovascular disease. Its approach pairs therapies given once a year with an AI-enabled tool that predicts a person's lifetime risk of the disease. Pulse 2.0 named that AI platform Klotho.
The therapies are small interfering RNA (siRNA) drugs, which switch off the production of a targeted protein. The company emerged in September 2025, according to BioSpace.
Maraganore, the former chief executive of Alnylam, and Clive Meanwell, who co-founded Metsera and led it as chief executive, are the two co-founders, according to BioSpace. Meanwell is also managing partner of Population Health Partners, one of the round's leads.
The pipeline
The lead programme, COR-1004, is an injectable siRNA that silences PCSK9 to lower LDL cholesterol. Forbion said dosing has started in a Phase 1 trial. BioSpace reported that the trial will assess safety and tolerability, with secondary goals of measuring clinical activity, including knockdown of plasma PCSK9 and serum LDL cholesterol. Initial proof-of-concept data are expected in 2026, according to Pulse 2.0.
A second programme, COR-2003, targets angiotensinogen to lower blood pressure. Pulse 2.0 reported that its Phase 1 trial is planned to start in mid-2026.
What the money is for
Forbion said the proceeds will advance the preventive RNAi medicine programme, which targets LDL cholesterol and blood pressure, and the development of Klotho. The sources do not give a breakdown of spending, a headcount or earlier funding rounds.
Meanwell said in the Pulse 2.0 report that the start of the first clinical trial "marks an important milestone on that journey". Maraganore said Corsera "has the potential to change the trajectory of cardiovascular disease".
Forbion quoted Meanwell as describing the company's aim as "a world without cardiovascular disease". The release named the same two targets as the focus for the money: LDL cholesterol, through COR-1004, and blood pressure, through the angiotensinogen programme that follows it into the clinic.
Who invested
Forbion is a European life sciences venture firm; its release was dated from Naarden in the Netherlands. Population Health Partners, the other co-lead, is the firm Meanwell manages. The only other named participant in the sources is Maraganore himself.
BioSpace named Corsera one of its NextGen companies to watch. Boorsma said in a statement that the company "exemplifies the kind of bold, science-driven innovation that Forbion aims to support and scale".
Company website: corserahealth.com